Gold bars to be exempt from tariffs, White House clarifies
Radiopharm Theranostics Ltd, a company specializing in pharmaceutical preparations, announced today a significant step in its operations with the signing of a supply agreement for non-carrier-added Lutetium-177, a radioisotope used in targeted cancer therapy. This agreement was disclosed in a public notice to the Australian Securities Exchange on Monday.
The supply contract was established with ITM, a company known for its production of medical radioisotopes. The announcement did not specify the financial terms or the duration of the agreement but highlighted the importance of securing a consistent supply of Lutetium-177 for Radiopharm’s product pipeline, which focuses on the development of targeted radiopharmaceuticals for the diagnosis and treatment of cancer.
Lutetium-177 is a key component in targeted radionuclide therapy, a form of treatment that delivers radiation directly to cancer cells while sparing healthy tissue. This method has gained attention in the pharmaceutical industry for its potential to improve treatment outcomes for patients with certain types of cancer.
The news comes at a time when the demand for radiopharmaceuticals is on the rise, driven by their growing role in precision medicine. The agreement is expected to support Radiopharm’s ongoing research and development efforts, as well as its future commercial activities.
This report, including the attached exhibit detailing the supply agreement, is not considered "filed" under the Securities Exchange Act of 1934 and is not incorporated by reference into any filing under the Securities Act of 1933, unless specifically referenced in such filing.
The information contained in this article is based on a press release statement. Radiopharm Theranostics Ltd, listed under the organization name 03 Life Sciences, has its principal executive office located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia. The company is incorporated in C3 and ends its fiscal year on June 30.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.